🇺🇸 AZD9150 in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug-Induced Liver Injury — 3 reports (16.67%)
  2. Pleural Effusion — 3 reports (16.67%)
  3. Lower Gastrointestinal Haemorrhage — 2 reports (11.11%)
  4. Mouth Haemorrhage — 2 reports (11.11%)
  5. Thrombocytopenia — 2 reports (11.11%)
  6. Transaminases Increased — 2 reports (11.11%)
  7. Adrenal Insufficiency — 1 report (5.56%)
  8. Alanine Aminotransferase Increased — 1 report (5.56%)
  9. Arthralgia — 1 report (5.56%)
  10. Aspartate Aminotransferase Increased — 1 report (5.56%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is AZD9150 approved in United States?

AZD9150 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for AZD9150 in United States?

Acerta Pharma BV is the originator. The local marketing authorisation holder may differ — check the official source linked above.